U.S. National Institute of Health www.cancer.gov National Cancer Institute
National Cancer Institute
Skip Header Navigation
Skip Navigation


Cancer is a devastating disease with an almost unfathomable impact individually on its victims and on populations worldwide. Cancer will take the life of 25 percent of the U.S. population; one in two men and one in three women will die from cancer. The potential impact of the aging of the baby boomers and other demographic effects will produce a significant increase in the numbers of new cancer cases (estimates range from 30 to 40 percent) in the next 10-20 years - at an ever increasing cost to our citizens. The NCI estimates that the economic impact of cancer in the United States is currently approximately $200 billion and we do not yet have a clear picture of how the increases in new cancer cases will translate into health care costs, but the potential is daunting. On the positive side, the cancer research communities, perhaps the largest group of scientists ever engaged in studying a specific disease, are generating data on many levels about cancer at an unprecedented pace.

Knowledge about cancer, hard won over the last few decades, is providing an ever increasing but fragmented picture of this complex of diseases at the genetic, molecular, and cellular levels. Translation of this knowledge into new cancer interventions has been, and remains, slow for a number of reasons, ranging from lack of U.S. infrastructure for translational research to the under-resourced development of science-based regulatory processes. Despite substantial progress in the biomolecular science of cancer, mortality rates have not improved much over the last several decades.

Cancer is classically defined as a disease of genetic alterations (inherited and acquired) and described as cells growing out of normal regulatory control. There are hundreds, perhaps thousands, of genetic changes in the over 200 diseases comprising cancer. Some of these mutations are critical to the cancer process (driver mutations) while others apparently are not (passenger mutations). These changes in the genome are translated into new messenger molecules and proteins that populate the intricate networks and signaling pathways that drive the function of both normal and cancerous cells, tissues, organs, and organisms. Describing and ultimately predictably understanding these integrated, often redundant, networks in normal and cancer cells represent two of the greatest interrelated scientific challenges of our time. It should also be noted that although cancer cells proliferate outside the realm of normal cellular regulation, they have the ability to control much of their own destiny on many levels - including occupying new biological spaces within the human host - growing uncontrollably, and eventually killing the host.

Adding to the complexity picture is the astounding pace of technology in biomedicine overall and particularly in cancer. Through the power of advanced technologies, the DNA of cancers is being sequenced, biomarkers of cancer are being explored, "signaling" pathways are under construction, and nanomedicine is developing quickly, to name a few advances. So if knowledge about cancer is accumulating on so many fronts, why was it important to hold a meeting where the intent was to explore how to best engage scientists from physics, mathematics, physical chemistry, and engineering in our national effort to conquer this horrific disease? Are there still problems left to solve that will benefit from these new fields? The answer to the question is a resounding yes. There are seminal questions that represent major barriers in cancer research today that will undoubtedly require new ideas, strategies, and approaches from the physical sciences to solve. In many ways, the more we know - the more complex the whole question of cancer and its control becomes - understanding this complexity will undoubtedly require significant knowledge and expertise from the physical sciences.

Currently cancer research overall does not broadly embrace physics, mathematics, physical chemistry, and critical fields of engineering through transdisciplinary efforts. These areas are often viewed as tangential to cancer research, and training in physics and mathematics is rarely available to career cancer biologists. In this regard, attempting to redirect well-trained cancer experts to achieve the goal of convergence of these fields is likely not a realistic approach.

It is becoming increasingly obvious, as we drill down into the molecular level of cancer, that addressing key basic questions surrounding areas such as energy and energy flows, short-range forces, cellular mechanics, and cell shape and tensegrity, as well as larger questions such as the physics of the metastatic process, is critical to understanding and controlling cancer. Cancer research needs new ideas, deep innovation, and new and unprecedented transdisciplinary teams of scientists to address these and other key questions. We have arrived at a point where understanding and controlling cancer will increasingly depend on the convergence of cancer research with the disciplines that comprise the physical sciences. We believe that the time is at hand to open this new frontier.

The first NCI-sponsored meeting to tackle this complex undertaking, "Integrating and Leveraging the Physical Sciences to Open a New Frontier in Oncology, was held in Washington, D.C., February 26-28, 2008. It was the beginning of a process of working with thought leaders from physics, mathematics, chemistry, nanotechnology, and engineering to achieve this audacious, but achievable, goal.

The meeting was, to say the least, interesting and provocative; participants challenged assumptions and offered innovative ideas and approaches, and many initiated dialogue on how to accomplish the integration of the physical sciences into the "fabric" of cancer research in the most effective manner, through new scientific collaborations.

Through the creation of this Web site, we have attempted to bring together in one place all of the various presentations, discussions, and emerging scientific focus areas that constituted the substance and output of the think tank. The site and meeting report will allow you to visit the very interesting opening presentation by Dr. Paul Davies and further explore the two intense days of keynote presentations, panel discussions, brainstorming sessions, and working group meetings. We encourage you to revisit the sessions and review the graphics for the various activities and the input from the working groups. Finally, we hope that you will visit the Forum noted as a tab at the top of the opening page of the Web site and participate fully in our discussions beyond the meeting.

The meeting was rich with innovative thinking, but a few areas of consensus emerged that are highlighted in the Forum: cancer's complexity; tumor cell evolution; information transfer in cancer; and a selected number of fundamental principles and laws of physics that have significant relevance in cancer. Many other innovative ideas were offered, and some of these should represent new areas of conversation to be opened in the Forum. We encourage you to be bold in expanding on the consensus areas and equally visionary in posing new questions for discussion. We have summarized what we currently see as next steps from the meeting in a separate section on this Web site, but these followup actions will continue to evolve in the next 6-8 weeks. So visit the Web site often to stay engaged and participate with us in opening this new frontier. Our special thanks go to all of our speakers, our facilitators, Robert Mittman and Thomas Benthin (graphics), and most especially to all of you who gave so freely of your time and shared your ideas.

Funding Opportunities
Find out more about funding opportunities available in physical sciences. More
Purple border
News & Events
Read the latest on Physical Sciences in Oncology and related activities. More


John E. Niederhuber, M.D.
John E. Niederhuber, M.D.
National Cancer Institute
Anna D. Barker, Ph.D.
Anna D. Barker, Ph.D.
Deputy Director
National Cancer Institute
Skip Footer Navigation